4.5 Article

Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses

期刊

BMC PULMONARY MEDICINE
卷 13, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2466-13-35

关键词

COPD; CAT; mMRC scores

资金

  1. Chonnam National University Hospital Research Institute of Clinical Medicine [CRI11008-1]

向作者/读者索取更多资源

Background: The GOLD 2011 document proposed a new classification system for COPD combining symptom assessment by COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores, and exacerbation risk. We postulated that classification of COPD would be different by the symptom scale; CAT vs mMRC. Methods: Outpatients with COPD were enrolled from January to June in 2012. The patients were categorized into A, B, C, and D according to the GOLD 2011; patients were categorized twice with mMRC and CAT score for symptom assessment, respectively. Additionally, correlations between mMRC scores and each item of CAT scores were analyzed. Results: Classification of 257 patients using the CAT score vs mMRC scale was as follows. By using CAT score, 60 (23.3%) patients were assigned to group A, 55 (21.4%) to group B, 21 (8.2%) to group C, and 121 (47.1%) to group D. On the basis of the mMRC scale, 97 (37.7%) patients were assigned to group A, 18 (7.0%) to group B, 62 (24.1%) to group C, and 80 (31.1%) to group D. The kappa of agreement for the GOLD groups classified by CAT and mMRC was 0.510. The mMRC score displayed a wide range of correlation with each CAT item (r = 0.290 for sputum item to r = 0.731 for dyspnea item, p < 0.001). Conclusions: The classification of COPD produced by the mMRC or CAT score was not identical. Care should be taken when stratifying COPD patients with one symptom scale versus another according to the GOLD 2011 document.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic significance of location index in resected T1-sized early-stage non-small cell lung cancer

Seung Wan Kang, Won Gi Jeong, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Byung Chan Lee, Yun-Hyeon Kim

Summary: This study aimed to determine the prognostic significance of central lung cancer in resected T1-sized early-stage non-small cell lung cancer (NSCLC). The results showed that central lung cancer, defined by a location index, was adversely associated with relapse-free survival and overall survival. It was found to be an independent adverse prognostic factor in early-stage NSCLC.

ACTA RADIOLOGICA (2023)

Article Oncology

Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial

Yong-Hyub Kim, Sung-Ja Ahn, Sung Ho Moon, Jin Hee Kim, Young-Chul Kim, In-Jae Oh, Cheol Kyu Park, Jae-Uk Jeong, Mee Sun Yoon, Ju-Young Song, Chang-Ok Suh, Kwan Ho Cho, Sun Hyo Park

Summary: We conducted a clinical trial to compare the efficacy of accelerated hypofractionated radiation therapy (RT) with conventionally fractionated 60-Gy RT in patients with stage III unresectable non-small cell lung cancer (NSCLC). The results showed no significant differences in treatment response, overall survival, progression-free survival, and local tumor control rates between the two groups. This suggests that accelerated hypofractionated RT may not be superior to conventional fractionation in patients with unresectable stage III NSCLC undergoing concurrent chemoradiation therapy.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Allergy

Impacts of Asthma in Patients With Bronchiectasis: Findings From the KMBARC Registry

Seong Mi Moon, Hayoung Choi, Hyung Koo Kang, Sei Won Lee, Yun Su Sim, Hye Yun Park, Yong-Soo Kwon, Sang-Heon Kim, Yeon-Mok Oh, Hyun Lee

Summary: This study evaluated 598 patients from the Korean Bronchiectasis Registry and found that bronchiectasis patients with asthma had higher BMI, more dyspnea, larger sputum volume, and lower FEV1 than those without asthma. Asthma was also associated with lower quality of life. Therefore, understanding the impacts of asthma in bronchiectasis is crucial for appropriate management.

ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2023)

Article Pharmacology & Pharmacy

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study

Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal, Jin Woo Song

Summary: This study evaluated the impact of reduced dose of pirfenidone on clinical outcomes in patients with IPF. The results showed that reduced doses did not have a negative impact on clinical outcomes compared to standard-dose pirfenidone, suggesting that dose reduction may be a useful method to manage adverse events while maintaining therapeutic efficacy.

FRONTIERS IN PHARMACOLOGY (2023)

Article Biochemical Research Methods

Deep learning model integrating positron emission tomography and clinical data for prognosis prediction in non-small cell lung cancer patients

Seungwon Oh, Sae-Ryung Kang, In-Jae Oh, Min-Soo Kim

Summary: The study aimed to improve survival prediction in patients with non-small cell lung cancer (NSCLC) by incorporating prognostic information from F-18 fluorodeoxyglucose positron emission tomography (FDG PET) images into a traditional survival prediction model using clinical data. The multimodal deep learning model showed the best performance, with a C-index and mean absolute error of 0.756 and 399 days under a five-fold cross-validation, respectively, followed by ResNet3D for PET (0.749 and 405 days) and CPH for clinical data (0.747 and 583 days).

BMC BIOINFORMATICS (2023)

Article Oncology

A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh

Summary: In this retrospective cohort study, durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) was found to be associated with survival benefits in real-world contexts, supporting its establishment as a new standard of care for stage III NSCLC. The study aimed to provide real-world evidence regarding the effectiveness and safety of DC after CCRT in the treatment of unresectable stage III NSCLC.

CANCERS (2023)

Article Oncology

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Cheol-Kyu Park, Sung-Woo Lee, Hyun-Ju Cho, Hyung-Joo Oh, Young-Chul Kim, Yong-Hyub Kim, Sung-Ja Ahn, Jae-Ho Cho, In-Jae Oh

Summary: A total of 50 patients with unresectable stage III NSCLC who received CCRT between March 2020 and March 2021 were recruited. Durvalumab consolidation (DC) was administered to patients (n=23) without progression after CCRT and programmed death-ligand 1 (PD-L1) ≥1%. Blood samples collected before (C0) and after CCRT (C1) were analyzed to calculate PBC counts and examine CTCs. The study found that the presence of residual CTC clusters at C1 and high platelet counts at C1 (PLThi) were independent risk factors for worse progression-free survival (PFS). The study suggests that the clearance of CTC clusters and platelet counts at C1 could serve as potential biomarkers for predicting survival.

CANCERS (2023)

Article Cell Biology

Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial

Cheol-Kyu Park, Ha Ra Jun, Hyung-Joo Oh, Ji-Young Lee, Hyun-Ju Cho, Young-Chul Kim, Jeong Eun Lee, Seong Hoon Yoon, Chang Min Choi, Jae Cheol Lee, Sung Yong Lee, Shin Yup Lee, Sung-Min Chun, In-Jae Oh

Summary: This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). The results suggest that baseline levels and dynamic changes of blood-based biomarkers can predict atezolizumab efficacy in previously treated NSCLC patients.
Article Oncology

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib

Ha-Young Park, Joo-Heon Park, Myung-Geun Shin, Seung Jung Han, Yong-Sok Ji, Hyung-Joo Oh, Young-Chul Kim, Taebum Lee, Yoo-Duk Choi, In-Jae Oh

Summary: This case report presents a rare case of ultra-late recurrence of NSCLC with choroidal metastasis and KIF13A-RET fusion in a 48-year-old female never-smoker. The patient had undergone lobectomy followed by adjuvant chemotherapy 14 years prior. Choroidal metastatic lesions were observed, along with bone and uterine metastases. Liquid-based NGS confirmed the presence of KIF13A-RET fusion, and the patient showed a partial response to selpercatinib therapy.

FRONTIERS IN ONCOLOGY (2023)

Letter Oncology

Role of adjuvant treatment in stage IB non-small cell lung carcinoma

Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Article Oncology

Healthcare utilization of lung cancer patients associated with exposure to fine particulate matter: A Korean cohort study

In-Jae Oh, Cheol-Kyu Park, Kyoung-Bok Min, Jin-Young Min, Chaeuk Chung, Seong-Hoon Yoon, Changsoo Kim, Sei-Hoon Yang

Summary: A study in Korea found that lung cancer patients exposed to high concentrations of PM2.5 had significantly increased healthcare utilization and drug prescriptions.

THORACIC CANCER (2023)

Article Medicine, General & Internal

Intracranial Efficacy of Systemic Therapy in Patients with Asymptomatic Brain Metastases from Lung Cancer

Min-Gwan Sun, Sue Jee Park, Yeong Jin Kim, Kyung-Sub Moon, In-Young Kim, Shin Jung, Hyung-Joo Oh, In-Jae Oh, Tae-Young Jung

Summary: There is ongoing controversy regarding whether to use radiologic follow-up or local treatment for asymptomatic small-sized brain metastases from primary lung cancer. This study evaluated the potential factors related to brain progression and the effectiveness of systemic therapy in controlling tumors without local treatment. The results showed that targeted therapy was superior to cytotoxic chemotherapy in the treatment of these brain metastases, offering the opportunity to determine the optimal timing for local treatment while reducing the risk of brain-related mortality.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Respiratory System

Nontuberculous mycobacterial pulmonary disease in a patient with unilateral pulmonary artery agenesis: Case report

Chang-Seok Yoon, Hwa-Kyung Park, Jae-Kyeong Lee, Bo -Gun Kho, Tae-Ok Kim, Hong-Joon Shin, Yong -Soo Kwon

Summary: This study presented a case of NTM pulmonary disease caused by a rare congenital lung disease. The patient was successfully treated with a combination of drugs for 16 months and achieved culture conversion without recurrence for 6 months.

RESPIRATORY MEDICINE CASE REPORTS (2023)

Article Oncology

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection

Hwa Kyung Park, Yoo Duk Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Young Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh

Summary: This study investigated the prevalence of genetic alterations in early-stage non-small cell lung cancer (NSCLC) and the association between EGFR mutations and recurrence after surgical resection. The presence of EGFR mutations was found to be an independent risk factor for recurrence and was associated with systemic recurrence. Targeted therapy should be considered more actively as an adjuvant or neoadjuvant treatment option.

CANCERS (2023)

Article Oncology

Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)

Wonjun Ji, In-Jae Oh, Cheol-Kyu Park, Sung Yong Lee, Juwhan Choi, Jae Cheol Lee, Jiwon Kim, Seung Hyeun Lee

Summary: This study provides real-world evidence of the effectiveness and safety of afatinib as a treatment option for patients with squamous cell carcinoma of the lung (LSCC) who have progressed after chemotherapy and immunotherapy. The study also highlights the potential predictive value of the ERBB2 mutation as a biomarker in clinical settings.

CANCERS (2023)

暂无数据